Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...

Telehealth company Hims & Hers Health (NYSE:HIMS) announced better-than-expected revenue in Q4 CY2024, with sales up 95.1% ...

Compounding pharmacy and IBD 50 newcomer Hims & Hers Health reported bullish earnings and sales growth late Monday. But Hims ...

Reports Q4 revenue $481.1M, consensus $470.5M. “2024 was a fantastic year at Hims and Hers as we continue to build a platform that leverages ...

Sees FY25 adjusted EBITDA of $270M to $320M vs. $176.9M in FY24, reflecting an Adjusted EBITDA margin of 12% to 13%.Discover the Best Stocks ...